Success in Phase III SINGLE trial of Dolutegravir

Interim results from the Phase III SINGLE study involving dolutegravir from Shionogi-Viiv HealthCare,demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla. At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50 copies ml) vs. 81% of participants on the single tablet regimen atripla: the difference in the primary endpoint was statistically significant. differences in efficacy were primarily driven by a higher rate of discontinuation due to adverse events on the atripla arm.>